Consolidated Portfolio Review Corp Ishares Tr Genomics Immunology Transaction History

Consolidated Portfolio Review Corp

  • $429 Billion
  • Q2 2024

A detailed history of Consolidated Portfolio Review Corp transactions in Ishares Tr Genomics Immunology stock. As of the latest transaction made, Consolidated Portfolio Review Corp holds 14,478 shares of IDNA stock, worth $353,407. This represents 0.08% of its overall portfolio holdings.

Number of Shares
14,478
Previous 14,063 2.95%
Holding current value
$353,407
Previous $339 Million 1.15%
% of portfolio
0.08%
Previous 0.09%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024
BUY
$21.71 - $24.69 $9,009 - $10,246
415 Added 2.95%
14,478 $335 Million
Q1 2024

Apr 30, 2024
BUY
$22.28 - $25.2 $18,002 - $20,361
808 Added 6.1%
14,063 $339 Million
Q4 2023

Jan 29, 2024
BUY
$17.37 - $23.3 $42,817 - $57,434
2,465 Added 22.85%
13,255 $305 Million
Q3 2023

Nov 13, 2023
SELL
$20.35 - $24.44 $52,340 - $62,859
-2,572 Reduced 19.25%
10,790 $220 Million
Q2 2023

Aug 14, 2023
SELL
$23.05 - $25.1 $43,702 - $47,589
-1,896 Reduced 12.43%
13,362 $312 Million
Q1 2023

May 11, 2023
BUY
$22.48 - $27.9 $342,999 - $425,698
15,258 New
15,258 $355 Million

Others Institutions Holding IDNA

# of Institutions
65
Shares Held
1.92M
Call Options Held
0
Put Options Held
0
View Full List

About ISHARES TR GENOMICS IMMUNOLOGY

IDNA Quotes by TradingView
  • Ticker IDNA
  • Sector ETFs
  • Industry ETFs
More about IDNA
Track This Portfolio

Track Consolidated Portfolio Review Corp Portfolio

Follow Consolidated Portfolio Review Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Consolidated Portfolio Review Corp, based on Form 13F filings with the SEC.

News

Stay updated on Consolidated Portfolio Review Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email